Press release
Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight | AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals
Dermatomyositis Treatment Market
The Dermatomyositis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Dermatomyositis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Dermatomyositis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Dermatomyositis market.
Discover which therapies are expected to grab the Dermatomyositis Market Share @ Dermatomyositis Market Outlook- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Dermatomyositis Market Report
• In July 2025, Pfizer announced results of a PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)
• In July 2025, AstraZeneca announced results of a Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
• In June 2025, argenx announced results of a Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis
• In May 2025, Galapagos NV announced results of a Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
• In March 2025:- Novartis Pharmaceuticals announced a study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies (IIM).
• In February 2025:- Galapagos NV conducted a study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM), followed by an open-label extension (OLE) period until Week 48.
• he total diagnosed prevalent cases of Dermatomyositis in the United States were around 38.5 thousand cases in 2023.
• The United States contributed to the largest diagnosed prevalent population of Dermatomyositis, acquiring ~54% of the 7MM in 2023. Whereas, EU4 and the UK, and Japan accounted for around 29% and 17% of the total population share, respectively, in 2023.
• Among the EU4 countries, Germany accounted for the largest number of diagnosed prevalent Dermatomyositis (5,272 Cases) cases followed by the UK (4,594 Cases), whereas Spain accounted for the lowest number of cases (3,053 Cases) in 2023.
• In 2023, it was estimated that there were around 15 thousand diagnosed cases in the age group of 40-59, followed by 13 thousand in 60-79 age group, 5,400 cases in 18-39 age group, 4,200 cases in 0-17 age group, and 1200 cases in 80 years and older in the US.
• According to DelveInsight estimates, in 2023 there were approximately 6,937 diagnosed prevalent cases of Mild type and about 5,476 cases of Moderate to severe type in Japan.
• In 2023, Dermatomyositis affected ~12 thousand males and ~26 thousand females in the United States.
• In 2023, DelveInsight analysis of the chronicity-specific data in the US revealed that 70% of people affected with Dermatomyositis have Chronic type, while 30% have the Acute Type.
• In Japan in 2023, comorbidity-specific cases accounted for the following percentages of diagnosed prevalent cases: ILD at 20%, CVD at 18%, cancer malignancy at 4%, and other conditions (including osteoporosis, dysphagia, Raynaud's syndrome, calcinosis, etc.) at 58%.
• The leading Dermatomyositis Companies such as AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
• Promising Dermatomyositis Pipeline Therapies such as Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others.
Stay ahead in the Dermatomyositis Therapeutics Market with DelveInsight's Strategic Report @ Dermatomyositis Market Outlook- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Epidemiology Segmentation in the 7MM
• Total Prevalence of Dermatomyositis
• Prevalent Cases of Dermatomyositis by severity
• Gender-specific Prevalence of Dermatomyositis
• Diagnosed Cases of Episodic and Chronic Dermatomyositis
Download the report to understand which factors are driving Dermatomyositis Epidemiology trends @ Dermatomyositis Prevalence- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Marketed Drugs
• OCTAGAM 10% (immunoglobulin): Octapharma
OCTAGAM 10% (immune globulin intravenous [human]) is the first and only intravenous immunoglobulin (IVIg) product indicated for the treatment of primary humoral immunodeficiency, chronic Immune Thrombocytopenic Purpura (ITP) and dermatomyositis. IVIG replacement therapy is the apparent treatment of choice for humoral primary immunodeficiency, such as dermatomyositis, as these patients cannot mount an effective immune response toward pathogens.
Dermatomyositis Emerging Drugs
• Brepocitinib: Priovant Therapeutics/Pfizer
Brepocitinib, being developed by Priovant Therapeutics, is an oral, once-daily dual inhibitor of TYK2 and JAK1. It targets the cytokine signaling pathways implicated in autoimmune diseases, including Type I and Type II interferon, IL-6, IL-12, and IL-23. This dual inhibition is intended to provide a broad suppression of these pathways, which are involved in the pathogenesis of dermatomyositis. Brepocitinib has shown promising results in several Phase II studies, demonstrating its efficacy and safety. Currently, it is being evaluated in a registrational Phase III trial specifically for dermatomyositis, aiming to address the significant unmet need for effective and convenient treatments for this condition.
• Efgartigimod: Argenx
Efgartigimod is an SC product combination of efgartigimod alfa and recombinant human hyaluronidase PH20 (rHuPH20). Efgartigimod targets the neonatal Fc receptor (FcRn) as a first-in-class investigational antibody fragment. Efgartigimod binds to the neonatal Fc receptor and inhibits its interaction with IgG, thereby reducing IgG recycling and increasing the degradation of IgG and pathological auto-antibodies without altering other immunoglobulins and albumin levels.
To learn more about Dermatomyositis treatment guidelines, visit @ Dermatomyositis Treatment Market Landscape- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dermatomyositis Market Outlook
There is no cure for dermatomyositis; however, medication can reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient's quality of life. The recent approval of OCTAGAM and the presence of several management guidelines, including the British Society for Rheumatology guideline, the Japanese Society of Rheumatology guideline, and others, have revolutionized the treatment landscape of dermatomyositis. Several other off-label medications, including corticosteroids, immunosuppressants, antimalarial drugs, antibiotics, and topical ointments, are used individually or in combination to eliminate symptoms.
Dermatomyositis Therapies and Companies
• Brepocitinib: Priovant Therapeutics, Inc.
• Lenabasum: Corbus Pharmaceuticals
• HIZENTRA: CSL Behring
• Ravulizumab: Alexion
• Lenabasum: Corbus Pharmaceuticals Inc.
• IMO-8400: Idera Pharmaceuticals
• GLPG3667: Galapagos NV
• M5049: EMD Serono
• human immunoglobulin G: CSL Behring
• PF-06823859: Pfizer
• Octagam: Octapharma
• KZR-616: Kezar Life Sciences, Inc.
• GB-0998: Japan Blood Products Organization
• H.P. Acthar Gel: Mallinckrodt
• Adrenocorticotropic Hormone Gel: Mallinckrodt
• tocilizumab: Genentech, Inc.
• Tacrolimus: Astellas Pharma Inc
• Rituximab: Biogen
Learn more about the FDA-approved drugs for Dermatomyositis @ Drugs for Dermatomyositis Treatment- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Dermatomyositis Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Dermatomyositis Companies: AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals, Holdings, Inc., Ermium Therapeutics, Kezar Life Sciences Inc., Néovacs, Horizon Therapeutics plc, Priovant Therapeutics, Inc., Corbus Pharmaceuticals, CSL Behring, Alexion, Corbus Pharmaceuticals Inc., Idera Pharmaceuticals, Galapagos NV, EMD Serono, Pfizer, Octapharma, Kezar Life Sciences, Inc., Japan Blood Products Organization, Mallinckrodt, Genentech, Inc., Astellas Pharma Inc, Biogen, and others
• Dermatomyositis Therapies: Brepocitinib, Lenabasum, HIZENTRA, Ravulizumab, Lenabasum, IMO-8400, GLPG3667, M5049, PF-06823859, Octagam, KZR-616, GB-0998, H.P. Acthar Gel, Adrenocorticotropic Hormone Gel, tocilizumab, Tacrolimus, Rituximab, and others
• Dermatomyositis Therapeutic Assessment: Dermatomyositis current marketed and Dermatomyositis emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis market drivers and Dermatomyositis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dermatomyositis Unmet Needs, KOL's views, Analyst's views, Dermatomyositis Market Access and Reimbursement
Discover more about Dermatomyositis Drugs in development @ Dermatomyositis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Dermatomyositis Market Report Introduction
2. Executive Summary for Dermatomyositis
3. SWOT analysis of Dermatomyositis
4. Dermatomyositis Patient Share (%) Overview at a Glance
5. Dermatomyositis Market Overview at a Glance
6. Dermatomyositis Disease Background and Overview
7. Dermatomyositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Dermatomyositis
9. Dermatomyositis Current Treatment and Medical Practices
10. Dermatomyositis Unmet Needs
11. Dermatomyositis Emerging Therapies
12. Dermatomyositis Market Outlook
13. Country-Wise Dermatomyositis Market Analysis (2020-2034)
14. Dermatomyositis Market Access and Reimbursement of Therapies
15. Dermatomyositis Market Drivers
16. Dermatomyositis Market Barriers
17. Dermatomyositis Appendix
18. Dermatomyositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dermatomyositis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight | AstraZeneca Plc., Bristol-Myers Squibb Company, Pfizer Inc., Octapharma AG, Corbus Pharmaceuticals here
News-ID: 4127256 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Dermatomyositis
Dermatomyositis market expected to reach USD 1.2 billion by 2034
Dermatomyositis is a rare, chronic autoimmune condition characterized by muscle inflammation and distinctive skin rashes. The disease impacts both adults and children, with complications that include interstitial lung disease and increased cancer risk. Despite its rarity, dermatomyositis places a significant burden on patients due to disability, reduced quality of life, and high treatment costs.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71381
In recent years, the dermatomyositis market has seen…
Dermatomyositis Market to Witness Promising Upswing by 2034, DelveInsight Foreca …
DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Dermatomyositis, historical and forecasted epidemiology as well as the Dermatomyositis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Dermatomyositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dermatomyositis Market Forecast
https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Dermatomyositis…
Dermatomyositis (DM) Market Emerging Trends and Growth Prospects 2034
Introduction
Dermatomyositis (DM) is a rare, chronic autoimmune inflammatory myopathy characterized by muscle weakness and distinctive skin rashes. It affects both adults and children and is associated with complications such as interstitial lung disease, malignancies, and cardiovascular involvement. The disease significantly reduces patient quality of life and requires long-term medical care.
Historically treated with corticosteroids and immunosuppressants, the market is now evolving with biologics, monoclonal antibodies, and targeted immunotherapies. Increasing global awareness…
Dermatomyositis Treatment Market Growth Accelerates: Strategic Forecast Predicts …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Dermatomyositis Treatment Industry Market Size Be by 2025?
The market for dermatomyositis treatment has seen significant expansion in the past few years. It is projected to escalate from $0.85 billion in 2024 to $0.91 billion in 2025, representing a compound annual growth rate (CAGR) of 7.2%.…
Dermatomyositis Market - Defying the challenges of dermatomyositis: choose our t …
Newark, New Castle, USA: The "Dermatomyositis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Dermatomyositis Market: https://www.growthplusreports.com/report/dermatomyositis-market/8675
This latest report researches the industry structure, sales, revenue, price and…
Dermatomyositis Market Size, Analysis, Share, Research, Business Growth and Fore …
Dermatomyositis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Dermatomyositis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It presents a close overview of the…
